Fundraising Fox
Pimera
San Diego, US · Delaware corporation
Find your way into Pimera
Sign up to see every warm intro you have to Pimera
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Pimera team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Pimera is a privately held biopharmaceutical company developing small-molecule cancer therapeutics, including RNA polymerase I inhibitors that activate nucleolar stress to treat hematologic and other cancers. It focuses on oncology drug discovery and development.
Founders & leadership
DD
Denis DryginFounder (former VP of R&D)Denis Drygin is a biotech scientist and executive with over two decades of experience in oncology drug discovery; he previously led preclinical and discovery efforts across multiple therapeutic programs at other companies and holds numerous patents and peer-reviewed publications in the field.
MH
Mustapha Haddach, Ph.D.President & CEO, Founder, Board Member
DD
Denis Drygin, Ph.D.Founder, Board Member
BT
Brian T. DorseyChief Development Officer (CDO)
MH
Mustapha HaddachFounder, President & CEO
Reported raises · per SEC filings
Form D private placements$2.2M disclosed across 1 round · 2020
▶$2.2MraisedMay 2020 · 13 investors · Other TechnologyRule 506(b)
▶$2.2MraisedMay 2020 · 13 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Mustapha HaddachExecutive Officer, Director
- Offering amount
- $6.5M
- Amount sold
- $2.2M
- First sale
- Feb 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
DecipheraDeciphera is a pharmaceutical company focused on developing treatments for people living with cancer. Its work centers on oncology drug development and support for patient communities.
Chimera BioengineeringChimera develops engineered cell therapies for cancer that produce therapeutic proteins only upon encountering tumor cells, using natural biological control mechanisms to improve safety and efficacy. The company focuses on treating solid tumors and other currently incurable cancers through localized, controlled immune cell activation.
Companies working in the same space as Pimera.
Frequently asked questions
- What does Pimera do?
- Pimera is a privately held biopharmaceutical company developing small-molecule cancer therapeutics, including RNA polymerase I inhibitors that activate nucleolar stress to treat hematologic and other cancers. It focuses on oncology drug discovery and development.
- Who founded Pimera?
- Pimera was founded by Denis Drygin, Mustapha Haddach, Ph.D., Denis Drygin, Ph.D..
- How much funding has Pimera raised?
- Pimera has disclosed $2.2M raised across 1 round.
- Where is Pimera headquartered?
- Pimera is headquartered in San Diego, US.